Company profile PCSA
After 38 days of this quarter the interest is at 160.0. Based on that we can calculate that during remaining 53 days it will total up to 383.0. Processa Pharmaceuticals expected interest is significantly higher compared to previous quarter (+2453.3%) and same quarter last year (+128.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 70 | 82 17.1% QoQ | 136 65.9% QoQ | 60 -55.9% QoQ |
| 2020 | 82 17.1% YoY 36.7% QoQ | 48 -41.5% YoY -41.5% QoQ | 66 -51.5% YoY 37.5% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2021 | 77 -6.1% YoY inf% QoQ | 34 -29.2% YoY -55.8% QoQ | 76 15.2% YoY 123.5% QoQ | 0 15.2% YoY -100.0% QoQ |
| 2022 | 162 110.4% YoY inf% QoQ | 35 2.9% YoY -78.4% QoQ | 21 -72.4% YoY -40.0% QoQ | 63 inf% YoY 200.0% QoQ |
| 2023 | 168 3.7% YoY 166.7% QoQ | 88 151.4% YoY -47.6% QoQ | 20 -4.8% YoY -77.3% QoQ | 15 -76.2% YoY -25.0% QoQ |
| 2024 | 160 -4.8% YoY 966.7% QoQ | - | - | - |
The average 5 years interest of Processa Pharmaceuticals was 5.61 per week. The last year interest of Processa Pharmaceuticals compared to the last 5 years has changed by 41.89%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 11.02%.
There is not enough data for Processa Pharmaceuticals stock to provide analysis
There is not enough data for Processa Pharmaceuticals stock to provide correlation calculation
There is not enough data for Processa Pharmaceuticals stock to provide analysis
There is not enough data for PCS499 clinical trials to provide analysis
There is not enough data for PCS499 clinical trials to provide correlation calculation
There is not enough data for PCS499 clinical trials to provide analysis
There is not enough data for PCS499 oral tablet to provide analysis
There is not enough data for PCS499 oral tablet to provide correlation calculation
There is not enough data for PCS499 oral tablet to provide analysis
There is not enough data for ulcerative necrobiosis lipoidica treatment to provide analysis
There is not enough data for ulcerative necrobiosis lipoidica treatment to provide correlation calculation
There is not enough data for ulcerative necrobiosis lipoidica treatment to provide analysis
There is not enough data for PCS12852 clinical trials to provide analysis
There is not enough data for PCS12852 clinical trials to provide correlation calculation
There is not enough data for PCS12852 clinical trials to provide analysis
There is not enough data for 5HT4 receptor agonist to provide analysis
There is not enough data for 5HT4 receptor agonist to provide correlation calculation
There is not enough data for 5HT4 receptor agonist to provide analysis
After 38 days of this quarter the interest is at 321.0. Based on that we can calculate that during remaining 53 days it will total up to 769.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 403 | 687 70.5% QoQ | 596 -13.2% QoQ | 643 7.9% QoQ |
| 2020 | 541 34.2% YoY -15.9% QoQ | 438 -36.2% YoY -19.0% QoQ | 572 -4.0% YoY 30.6% QoQ | 536 -16.6% YoY -6.3% QoQ |
| 2021 | 574 6.1% YoY 7.1% QoQ | 649 48.2% YoY 13.1% QoQ | 670 17.1% YoY 3.2% QoQ | 649 21.1% YoY -3.1% QoQ |
| 2022 | 677 17.9% YoY 4.3% QoQ | 699 7.7% YoY 3.2% QoQ | 696 3.9% YoY -0.4% QoQ | 644 -0.8% YoY -7.5% QoQ |
| 2023 | 699 3.2% YoY 8.5% QoQ | 888 27.0% YoY 27.0% QoQ | 882 26.7% YoY -0.7% QoQ | 904 40.4% YoY 2.5% QoQ |
| 2024 | 321 -54.1% YoY -64.5% QoQ | - | - | - |
The average 5 years interest of gastroparesis treatment was 51.22 per week. The last year interest of gastroparesis treatment compared to the last 5 years has changed by 27.43%. The interest for gastroparesis treatment is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 33.2%.
There is not enough data for PCS3117 clinical trials to provide analysis
There is not enough data for PCS3117 clinical trials to provide correlation calculation
There is not enough data for PCS3117 clinical trials to provide analysis
There is not enough data for PCS6422 clinical trials to provide analysis
There is not enough data for PCS6422 clinical trials to provide correlation calculation
There is not enough data for PCS6422 clinical trials to provide analysis
There is not enough data for PCS11T cancer treatment to provide analysis
There is not enough data for PCS11T cancer treatment to provide correlation calculation
There is not enough data for PCS11T cancer treatment to provide analysis